List of Excipients in Branded Drug ERGOCALCIFEROL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Torrent Pharmaceuticals Limited	ERGOCALCIFEROL	ergocalciferol	13668-757	BUTYLATED HYDROXYANISOLE
Torrent Pharmaceuticals Limited	ERGOCALCIFEROL	ergocalciferol	13668-757	FD&C BLUE NO. 1
Torrent Pharmaceuticals Limited	ERGOCALCIFEROL	ergocalciferol	13668-757	FD&C YELLOW NO. 5
Torrent Pharmaceuticals Limited	ERGOCALCIFEROL	ergocalciferol	13668-757	GELATIN
Torrent Pharmaceuticals Limited	ERGOCALCIFEROL	ergocalciferol	13668-757	GLYCERIN
Torrent Pharmaceuticals Limited	ERGOCALCIFEROL	ergocalciferol	13668-757	SOYBEAN OIL
Torrent Pharmaceuticals Limited	ERGOCALCIFEROL	ergocalciferol	13668-757	WATER

Generic Drugs Containing ERGOCALCIFEROL

Company	Ingredient	NDC	Excipient
Blenheim Pharmacal Inc	ergocalciferol	10544-527	D&C YELLOW NO. 10
Blenheim Pharmacal Inc	ergocalciferol	10544-527	FD&C BLUE NO. 1
Blenheim Pharmacal Inc	ergocalciferol	10544-527	GELATIN
Blenheim Pharmacal Inc	ergocalciferol	10544-527	GLYCERIN
Blenheim Pharmacal Inc	ergocalciferol	10544-527	SOYBEAN OIL
Blenheim Pharmacal Inc	ergocalciferol	10544-527	WATER
Aidarex Pharmaceuticals LLC	ergocalciferol	33261-730	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in ERGOCALCIFEROL?

# Of NDCs	Excipient
5	BENZYL ALCOHOL
4	BUTYLATED HYDROXYANISOLE
5	BUTYLPARABEN
1	CI 77891
43	D&C YELLOW NO. 10
4	DIMETHICONE
43	FD&C BLUE NO. 1

Ergocalciferol Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Ergocalciferol, or vitamin D2, is an off-patent, fat-soluble small molecule with limited active-ingredient exclusivity. Commercial value is concentrated in formulation performance, dosage-form convenience, stability, palatability, dietary positioning, and combination products. The strongest opportunities are high-dose oral products, pediatric liquid formulations, vegan and allergen-controlled products, dispersible tablets, and stable lipid or self-emulsifying systems.

What is the commercial position of ergocalciferol?

Ergocalciferol is vitamin D2, a secosteroid used to prevent and treat vitamin D deficiency and related disorders. It is marketed as a prescription drug, an over-the-counter product, and an ingredient in dietary supplements. High-dose prescription presentations commonly include 50,000 IU capsules, while lower-strength products are sold as tablets, capsules, softgels, liquids, and drops.

The active ingredient is established and inexpensive. The commercial challenge is differentiation rather than discovery.

Commercial factor	Ergocalciferol position
Active ingredient	Established small molecule
Biologic or biosimilar status	Not applicable
Primary therapeutic use	Vitamin D deficiency and related disorders
Solubility	Practically insoluble in water; lipophilic
Common prescription strength	50,000 IU
Common consumer formats	Softgels, capsules, tablets, drops, gummies, liquids
Core formulation issue	Uniformity, oxidation control, light protection, and dispersion
Core regulatory routes	ANDA, 505(b)(2), OTC drug pathway, or dietary supplement pathway
Core patent exposure	Generally low for the active ingredient
Commercial differentiation	Formulation, dosage form, excipient system, claims, packaging, and channel

FDA-approved prescription ergocalciferol products include high-dose oral dosage forms and oral solutions. The FDA-approved labeling for Drisdol describes ergocalciferol oral solution and identifies the drug as a treatment for vitamin D deficiency and hypoparathyroidism-related conditions.[1]

What excipient properties matter most for ergocalciferol?

Ergocalciferol has low aqueous solubility and is sensitive to environmental degradation, particularly light, oxygen, heat, and unsuitable storage conditions. Excipients must support dose uniformity and chemical stability without creating unacceptable taste, gastrointestinal tolerability, or regulatory burdens.

Lipid vehicles

Lipid vehicles are the most established excipient platform for ergocalciferol. Suitable oils can dissolve or disperse the active ingredient and support softgel, oral-drop, and liquid formulations.

Common commercial categories include:

• Medium-chain triglycerides
• Long-chain vegetable oils
• Refined soybean, corn, sunflower, or olive-derived oils
• Fractionated coconut-derived oils
• Synthetic or semisynthetic triglyceride systems

The choice of oil affects oxidative stability, capsule compatibility, viscosity, fill weight, dose uniformity, and consumer positioning. Medium-chain triglycerides may support lower viscosity and improved handling. Highly unsaturated oils can require stronger antioxidant and oxygen-control strategies.

Surfactants and self-emulsifying systems

Surfactants and cosolvents can improve dispersion in gastrointestinal fluids. Self-emulsifying drug-delivery systems may create a smaller droplet size after administration and reduce dependence on meal-related fat intake.

Potential excipient categories include:

• Nonionic surfactants
• Phospholipids
• Polyethylene glycol-based surfactants
• Propylene glycol or glycerol-based cosolvents
• Mixed lipid-surfactant systems

These systems create a stronger formulation patent position than a conventional oil-filled capsule, but they also create greater regulatory and development risk. The key evidence is not simply higher assay or faster dissolution. Developers need data on content uniformity, chemical stability, biorelevant dispersion, dose recovery, and comparative exposure where a 505(b)(2) strategy is contemplated.

Antioxidants and chelators

Antioxidants can protect the active ingredient and oil phase from oxidative degradation. Depending on the formulation, developers may evaluate tocopherols, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, or other permitted antioxidant systems.

The appropriate choice depends on:

• Compatibility with the oil vehicle
• Peroxide formation
• Container-closure oxygen transmission
• Sensory impact
• Daily excipient exposure
• Existing FDA Inactive Ingredient Database precedent

Chelating agents may be useful where trace metals accelerate degradation. Their value is formulation-specific and must be demonstrated through stability studies rather than assumed from general antioxidant claims.

Suspending and wetting agents

For tablets, suspensions, and aqueous oral products, wetting agents and suspending systems can reduce settling and improve dose recovery. Relevant categories include cellulose derivatives, povidone, polysorbates, poloxamers, gums, and inorganic suspending agents.

A liquid product must meet a higher practical standard than chemical assay alone. It should provide consistent dose delivery after storage, shaking, partial use, temperature changes, and repeated opening.

Sweeteners, flavors, and taste-masking systems

Ergocalciferol itself is used at very low mass quantities relative to the labeled international-unit dose, but the formulation may still have an undesirable oil taste or odor. Pediatric products need a complete taste and swallowability strategy.

Options include:

• Sucrose, glucose, or polyols
• Sucralose, acesulfame potassium, or other high-intensity sweeteners
• Fruit or vanilla flavor systems
• Microencapsulation
• Flavored lipid emulsions
• Coated multiparticulates

Sugar-free and alcohol-free formulations can target pediatric, diabetic, geriatric, and institutional markets. However, polyols can create gastrointestinal tolerability issues, while some flavor systems can complicate preservative and packaging compatibility.

What formulations are protected by ergocalciferol excipient strategy?

A conventional ergocalciferol capsule is difficult to protect broadly because the active ingredient, common oil vehicles, and standard capsule technologies are well known. More defensible intellectual property usually requires a measurable technical distinction.

Formulation categories with commercial potential

Formulation	Main commercial benefit	Patent potential
Oil-filled softgel	Familiar delivery and high dose loading	Low to moderate
Medium-chain triglyceride liquid	Dropper dosing and simplified excipient profile	Moderate
Self-emulsifying capsule	Improved dispersion and meal independence	Moderate to high
Dry powder tablet	Better portability and vegetarian positioning	Moderate
Orally disintegrating tablet	Rapid administration without water	Moderate
Pediatric suspension	Flexible dosing and adherence	Moderate
Microencapsulated powder	Taste masking and stability	Moderate to high
Chewable or gummy	Consumer adherence and supplement positioning	Low to moderate
Combination product	Therapeutic convenience	Moderate, depending on combination

A formulation patent should focus on defined composition ranges, stability thresholds, particle-size distribution, dissolution or dispersion behavior, and packaging interaction. Broad claims covering "ergocalciferol with an oil" are likely to face prior-art and obviousness challenges.

How should developers design an ergocalciferol excipient platform?

A practical development strategy begins with the target product profile rather than the excipient list.

Prescription 50,000 IU capsule

For a high-dose prescription product, the priority is dose uniformity, stability, manufacturability, and low cost. An oil-filled softgel or hard capsule with a controlled lipid fill may be commercially sufficient. A differentiated product needs a specific advantage, such as:

• Reduced sensitivity to food intake
• Lower capsule size
• Improved shelf life
• Better dose recovery at low fill volumes
• Vegan or bovine-free capsule shell
• Improved stability under warehouse temperature excursions

Pediatric oral liquid

The main risks are sedimentation, adsorption to the container, microbial control, taste, and dosing-device accuracy. A developer should consider a low-volume, concentrated liquid with a calibrated oral syringe rather than a large-volume suspension.

The formulation should be tested for:

• Uniformity at the beginning, middle, and end of the bottle
• Dose recovery through the supplied device
• Stability after repeated opening
• Light exposure
• Freeze-thaw and elevated-temperature conditions
• Compatibility with polyethylene, polypropylene, and glass containers

Water-dispersible or dry powder product

A water-dispersible powder can target patients who cannot swallow capsules and consumers seeking a non-oily product. Spray drying, adsorption onto porous carriers, solid dispersion, or multiparticulate technologies may support this format.

The product must control electrostatic behavior, segregation, moisture uptake, reconstitution time, and active-content uniformity. A dry product that disperses poorly may have weaker real-world performance than a simple oil formulation.

Vegan and allergen-controlled product

Vegan capsules, plant-derived excipients, and allergen-controlled manufacturing can support premium positioning. The commercial value is higher in dietary supplements and direct-to-consumer channels than in conventional generic prescription markets.

The formulation should document:

• Capsule-shell origin
• Oil source
• Processing aids
• Cross-contact controls
• Label claims
• Stability differences from gelatin-based systems

What is the FDA regulatory status of ergocalciferol?

Ergocalciferol can be developed through several regulatory routes, depending on the intended claims, strength, dosage form, and product positioning.

ANDA pathway

A generic prescription product can generally use the ANDA pathway when it demonstrates pharmaceutical equivalence and bioequivalence to a reference listed drug. The applicant must address strength, dosage form, route, inactive ingredients, labeling, manufacturing, and stability.[2]

For an oral solution, the key regulatory issues may include sameness of active concentration, excipient acceptability, preservative content, dose-delivery performance, and labeling. For a softgel or capsule, in vivo bioequivalence may be relevant because the lipid system can affect absorption.

505(b)(2) pathway

A novel delivery system, revised dosage form, or formulation with a clinical or pharmacokinetic distinction may fit the 505(b)(2) pathway. This route can support a product with a new formulation or delivery technology while relying partly on existing FDA findings.[3]

The commercial case must justify the development cost. A 505(b)(2) application is more attractive where the product provides a clear benefit, such as:

• Improved absorption under low-fat meal conditions
• Reduced dosing frequency
• Pediatric administration
• Improved stability
• A novel route or dosage form
• A clinically meaningful adherence advantage

Dietary supplement pathway

Vitamin D2 supplements generally fall under the dietary supplement framework when marketed with permitted structure-function claims and without disease-treatment claims. FDA does not preapprove dietary supplements for safety or effectiveness before marketing in the same manner as prescription drugs.[4]

The supplement route has lower clinical-development cost but creates constraints on disease claims, product positioning, manufacturing controls, and evidence standards. A product marketed to treat vitamin D deficiency requires careful assessment of whether its claims place it in drug territory.

FDA Inactive Ingredient Database

The FDA Inactive Ingredient Database is a central tool for excipient selection. Existing use levels and routes of administration can reduce regulatory friction, while novel excipients or substantially higher exposure levels may require additional justification.[5]

A development team should evaluate the database at the beginning of formulation work, not after the formulation is fixed.

When does ergocalciferol lose exclusivity?

Ergocalciferol is generally regarded as an off-patent active ingredient. Its commercial exclusivity is not comparable to that of a recently approved small molecule or biologic.

Patent and regulatory exclusivity

Exclusivity type	Ergocalciferol position
Composition-of-matter patent	Generally expired or not commercially controlling
New chemical entity exclusivity	Not relevant to current products
Orphan exclusivity	Not generally controlling for standard vitamin D2 products
Biosimilar exclusivity	Not applicable
Formulation patents	Possible for specific technologies
Method-of-use patents	Possible but generally narrow
Pediatric exclusivity	Product-specific and not a general D2 barrier
Orange Book patents	Must be reviewed by product and NDA
Generic entry	Primarily controlled by ANDA approval, labeling, manufacturing, and litigation risks

The Orange Book remains the relevant source for listed patents and exclusivity associated with approved prescription products.[6] A specific formulation or method-of-use patent can delay or complicate generic entry, but the industry-wide active ingredient is not protected by a single dominant patent estate.

What is the Orange Book status of ergocalciferol?

Orange Book analysis must be performed at the product level because listings attach to specific approved applications, not to every commercial use of ergocalciferol. Prescription products may have different application histories, strengths, dosage forms, and patent records.

For business planning, the relevant review should cover:

• Approved application number
• Reference listed drug status
• Listed patents
• Patent-use codes
• Expiration dates
• Paragraph IV certifications
• Approved dosage forms and strengths
• Whether the product remains actively marketed

Nonprescription supplements and many OTC vitamin D products do not have Orange Book listings because they are not approved prescription NDAs.

Which companies are challenging ergocalciferol patents?

The generic market is fragmented, with multiple manufacturers and private-label suppliers offering vitamin D2 products. Because ergocalciferol is mature, competition is more likely to arise through routine ANDA approvals, contract manufacturing, supplement launches, and formulation substitutions than through high-profile patent litigation.

No broad biosimilar challenge exists because ergocalciferol is a chemically defined small molecule, not a biologic. Paragraph IV activity is relevant only if a particular approved reference product has an unexpired Orange Book-listed patent. It is not a general barrier to vitamin D2 entry.

A generic entrant should evaluate patent risk separately for:

1. The active ingredient.
2. The reference product’s formulation.
3. Method-of-use claims.
4. Manufacturing processes.
5. Device or dosing-system patents.
6. Packaging or stability technologies.

What patent litigation and settlement risks affect ergocalciferol?

The principal litigation risk is likely to involve a differentiated formulation rather than vitamin D2 itself. A company seeking protection for a novel lipid system, dispersible powder, pediatric suspension, or combination product should expect scrutiny under obviousness, written description, enablement, and anticipation standards.

Potential settlement structures in a Paragraph IV case could include:

• Early generic entry on a specified date
• Entry limited to non-patented indications
• License rights for a formulation patent
• Agreement restricting an infringing dosage form
• Authorized-generic arrangements
• No-challenge provisions, subject to antitrust limits

Because formulation patents may be narrow, a settlement can preserve value only if the patent covers a commercially important dosage form or clinically relevant use.

How strong is the ergocalciferol patent estate?

The core patent estate is weak because the active ingredient is old and widely used. Product-level protection can still be moderate where the formulation has a clear technical effect and narrow competitors cannot easily design around it.

Asset type	Relative strength
Ergocalciferol composition patent	Very low
Conventional capsule or softgel	Low
Specific excipient ratio	Low to moderate
Self-emulsifying system with measured performance	Moderate
Pediatric taste-masked formulation	Moderate
Novel device or dosing system	Moderate
Combination with another active ingredient	Moderate, depending on claims
Manufacturing process with defined impurity control	Moderate
Trade secret manufacturing parameters	Useful but difficult to enforce against independent development

The strongest protection is likely to combine patents with trade secrets, manufacturing know-how, supplier qualification, stability data, packaging controls, and brand positioning.

What commercial opportunities exist in ergocalciferol?

The most attractive opportunities are not broad commodity capsules. They are targeted products that solve a measurable administration or stability problem.

High-potential segments

1. Pediatric deficiency treatment
   Low-volume liquids, unit-dose sachets, and taste-masked suspensions can improve dosing accuracy and adherence.

2. Vegan and allergen-controlled products
   Plant-based capsule shells and documented excipient sourcing can command premium pricing in supplement and specialty pharmacy channels.

3. Water-dispersible products
   These can target consumers who dislike oils or cannot swallow softgels.

4. High-dose adherence products
   Weekly or monthly administration formats may support clinical convenience, subject to medical and labeling requirements.

5. Hospital and institutional products
   Unit-dose packaging, clear dose labeling, tamper evidence, and low error rates can differentiate otherwise low-cost products.

6. Combination formulations
   Ergocalciferol combined with calcium, magnesium, or other deficiency-management ingredients may reduce pill burden. Combination products face greater stability, regulatory, and claim complexity.

7. Stable liquid concentrates
   Improved light and oxygen protection can support longer shelf life and reduced product loss in pharmacy and home-use settings.

How does ergocalciferol compare with cholecalciferol?

Cholecalciferol, or vitamin D3, is the main commercial competitor. Many consumers and clinicians perceive D3 as more effective or longer-lasting, although product selection depends on clinical context, formulation, dose, and regulatory claims.

Attribute	Ergocalciferol, vitamin D2	Cholecalciferol, vitamin D3
Source positioning	Often fungal or plant-derived	Often lanolin-derived; vegan versions exist
Prescription high-dose use	Established	Established
Supplement competition	Strong but generally secondary	Dominant in many markets
Formulation challenge	Lipophilicity and stability	Similar lipophilicity and stability
Vegan positioning	Potentially strong	Requires specific source and documentation
Differentiation opportunity	Pediatric, vegan, specialty dosing	Broad consumer and clinical market
Patent barrier	Generally low	Generally low for standard products

Ergocalciferol can compete effectively where source, dosage form, price, or clinical preference matters. A new product should not assume that a standard D2 capsule can displace established D3 products without a clear market reason.

What revenue exposure and licensing opportunities exist?

Public companies generally do not report ergocalciferol revenue as a separate line item. Revenue exposure is usually embedded in broader vitamin, generic, consumer-health, or specialty-pharmaceutical categories.

Licensing opportunities are most credible in:

• Novel excipient systems
• Oral delivery platforms
• Pediatric taste masking
• Vegan softgel technology
• Unit-dose packaging
• Combination-product rights
• Regional registration and distribution
• Contract manufacturing with validated stability data

A licensing deal based only on the right to sell conventional ergocalciferol is unlikely to command strong economics. A platform with demonstrated stability, bioavailability, manufacturing scale, and regulatory precedent has greater value.

Key Takeaways

• Ergocalciferol is an established, off-patent small molecule with low active-ingredient exclusivity.
• The principal commercial opportunity lies in formulation and administration rather than molecule ownership.
• Lipid vehicles, self-emulsifying systems, antioxidants, suspending agents, and taste-masking technologies are the main excipient tools.
• Pediatric liquids, water-dispersible powders, vegan products, unit-dose formats, and stable high-dose capsules offer the clearest differentiation paths.
• The FDA ANDA route is appropriate for conventional generic products; 505(b)(2) may support genuinely differentiated delivery systems.
• Orange Book and Paragraph IV risk must be assessed for each approved reference product, not for ergocalciferol as a molecule.
• Biosimilar risk is irrelevant because ergocalciferol is not a biologic.
• Patent protection is generally weak for conventional formulations and stronger only where composition, performance, and technical effect are narrowly defined.
• Commercial success depends on stability, dose accuracy, source positioning, packaging, and channel strategy.

FAQs

Can ergocalciferol be formulated as a water-soluble tablet?

Yes. Developers can use dispersions, solid carriers, surfactants, microencapsulation, or solid-dispersion technologies. The product must demonstrate uniformity, acceptable dissolution or dispersion, stability, and consistent dose delivery.

Are vegan ergocalciferol products commercially viable?

Yes. Vitamin D2 can support vegan positioning, particularly when the active ingredient, capsule shell, oils, processing aids, and packaging materials are documented. The claim has greater value in supplements and consumer health than in commodity prescription generics.

Does ergocalciferol require a biosimilar development strategy?

No. Ergocalciferol is a chemically defined small molecule. Generic development normally proceeds through an ANDA or, for a differentiated product, a 505(b)(2) application.

Can a new excipient create patent protection for vitamin D2?

Potentially, but the patent must claim a novel and non-obvious formulation with a defensible technical effect. A generic combination of ergocalciferol and a conventional oil is unlikely to provide strong protection by itself.

Is cholecalciferol a stronger commercial product than ergocalciferol?

Cholecalciferol has broader consumer-market recognition and often greater supplement demand. Ergocalciferol remains commercially relevant in prescription products, vegan positioning, specialty dosing, and products where source or clinical preference supports vitamin D2 use.

References

1. U.S. Food and Drug Administration. (n.d.). Drisdol (ergocalciferol) oral solution prescribing information.
2. U.S. Food and Drug Administration. (2024). Generic drug facts.
3. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2024). Questions and answers on dietary supplements.
5. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
7. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products.
8. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products.